Epigenomics AG (EPGNF)
USD 0.79
(0.09%)
USD 0.79
(0.09%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 20.86 Million EUR | 267.26% |
| 2022 | 5.68 Million EUR | 123.36% |
| 2021 | 2.54 Million EUR | -13.3% |
| 2020 | 2.93 Million EUR | -32.73% |
| 2019 | 4.36 Million EUR | 35.66% |
| 2018 | 3.21 Million EUR | -65.05% |
| 2017 | 9.19 Million EUR | 142.13% |
| 2016 | 3.79 Million EUR | -30.95% |
| 2015 | 5.5 Million EUR | 5.53% |
| 2014 | 5.21 Million EUR | 12.77% |
| 2013 | 4.62 Million EUR | 69.93% |
| 2012 | 2.72 Million EUR | -17.0% |
| 2011 | 3.27 Million EUR | 28.86% |
| 2010 | 2.54 Million EUR | -40.44% |
| 2009 | 4.27 Million EUR | 14.94% |
| 2008 | 3.71 Million EUR | -27.06% |
| 2007 | 5.09 Million EUR | 204.24% |
| 2006 | 1.67 Million EUR | -70.22% |
| 2005 | 5.62 Million EUR | 1.39% |
| 2004 | 5.54 Million EUR | -59.21% |
| 2003 | 13.59 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 Q2 | 2.3 Million EUR | -64.69% |
| 2023 Q1 | 6.53 Million EUR | 15.07% |
| 2023 Q3 | 20.86 Million EUR | 803.83% |
| 2023 FY | 20.86 Million EUR | 267.26% |
| 2023 Q4 | 20.86 Million EUR | 0.0% |
| 2022 Q2 | 3.95 Million EUR | 17.99% |
| 2022 Q3 | 5.03 Million EUR | 27.39% |
| 2022 Q4 | 5.68 Million EUR | 12.77% |
| 2022 FY | 5.68 Million EUR | 123.36% |
| 2022 Q1 | 3.35 Million EUR | 31.77% |
| 2021 FY | 2.54 Million EUR | -13.3% |
| 2021 Q4 | 2.54 Million EUR | -8.43% |
| 2021 Q2 | 3.32 Million EUR | 10.23% |
| 2021 Q3 | 2.77 Million EUR | -16.58% |
| 2021 Q1 | 3.02 Million EUR | 2.97% |
| 2020 Q2 | 3.72 Million EUR | -48.84% |
| 2020 Q1 | 7.27 Million EUR | 66.95% |
| 2020 Q4 | 2.93 Million EUR | -10.74% |
| 2020 FY | 2.93 Million EUR | -32.73% |
| 2020 Q3 | 3.28 Million EUR | -11.76% |
| 2019 Q3 | 4.03 Million EUR | 5.05% |
| 2019 FY | 4.36 Million EUR | 35.66% |
| 2019 Q2 | 3.84 Million EUR | 33.84% |
| 2019 Q1 | 2.87 Million EUR | -10.64% |
| 2019 Q4 | 4.36 Million EUR | 7.97% |
| 2018 FY | 3.21 Million EUR | -65.05% |
| 2018 Q4 | 3.21 Million EUR | -68.21% |
| 2018 Q2 | 9.12 Million EUR | 1.29% |
| 2018 Q1 | 9.01 Million EUR | -2.02% |
| 2018 Q3 | 10.11 Million EUR | 10.79% |
| 2017 FY | 9.19 Million EUR | 142.13% |
| 2017 Q4 | 9.19 Million EUR | -1.95% |
| 2017 Q3 | 9.37 Million EUR | 114.28% |
| 2017 Q2 | 4.37 Million EUR | 42.25% |
| 2017 Q1 | 3.07 Million EUR | -18.98% |
| 2016 Q2 | 8.58 Million EUR | 11.65% |
| 2016 Q4 | 3.79 Million EUR | -31.63% |
| 2016 FY | 3.79 Million EUR | -30.95% |
| 2016 Q1 | 7.68 Million EUR | 39.73% |
| 2016 Q3 | 5.55 Million EUR | -35.26% |
| 2015 Q1 | 6.17 Million EUR | 18.55% |
| 2015 FY | 5.5 Million EUR | 5.53% |
| 2015 Q2 | 6.4 Million EUR | 3.71% |
| 2015 Q4 | 5.5 Million EUR | -19.83% |
| 2015 Q3 | 6.86 Million EUR | 7.05% |
| 2014 Q4 | 5.21 Million EUR | 9.24% |
| 2014 Q2 | 5 Million EUR | 5.95% |
| 2014 FY | 5.21 Million EUR | 12.77% |
| 2014 Q1 | 4.72 Million EUR | 2.14% |
| 2014 Q3 | 4.77 Million EUR | -4.62% |
| 2013 Q3 | 2.18 Million EUR | 18.05% |
| 2013 Q4 | 4.62 Million EUR | 111.63% |
| 2013 FY | 4.62 Million EUR | 69.93% |
| 2013 Q2 | 1.85 Million EUR | -16.29% |
| 2013 Q1 | 2.21 Million EUR | -18.75% |
| 2012 Q3 | 3.57 Million EUR | 14.91% |
| 2012 FY | 2.72 Million EUR | -17.0% |
| 2012 Q4 | 2.72 Million EUR | -23.94% |
| 2012 Q2 | 3.11 Million EUR | 22.47% |
| 2012 Q1 | 2.54 Million EUR | -22.46% |
| 2011 Q1 | 2.61 Million EUR | 2.83% |
| 2011 Q2 | 2.7 Million EUR | 3.25% |
| 2011 Q3 | 4.12 Million EUR | 52.81% |
| 2011 Q4 | 3.27 Million EUR | -20.58% |
| 2011 FY | 3.27 Million EUR | 28.86% |
| 2010 Q4 | 2.54 Million EUR | -13.06% |
| 2010 FY | 2.54 Million EUR | -40.44% |
| 2010 Q1 | 4.19 Million EUR | -1.78% |
| 2010 Q2 | 2.9 Million EUR | -30.85% |
| 2010 Q3 | 2.92 Million EUR | 0.86% |
| 2009 Q4 | 4.27 Million EUR | 0.0% |
| 2009 FY | 4.27 Million EUR | 14.94% |
| 2008 FY | 3.71 Million EUR | -27.06% |
| 2007 FY | 5.09 Million EUR | 204.24% |
| 2006 FY | 1.67 Million EUR | -70.22% |
| 2005 FY | 5.62 Million EUR | 1.39% |
| 2004 FY | 5.54 Million EUR | -59.21% |
| 2003 FY | 13.59 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| American Bio Medica Corporation | 3.6 Million USD | -478.168% |
| Arrayit Corporation | 7.49 Million USD | -178.264% |
| Atlantic International Corp. | 3.82 Million USD | -444.852% |
| Biocept, Inc. | 22.01 Million USD | 5.236% |
| Bioqual, Inc. | 18.93 Million USD | -10.151% |
| CardioGenics Holdings Inc | 1.79 Million USD | -1062.183% |
| DermTech, Inc. | 64.75 Million USD | 67.786% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 734.97 Million USD | 97.162% |
| HTG Molecular Diagnostics, Inc. | 12.38 Million USD | -68.419% |
| iMD Companies, Inc. | 1.67 Million USD | -1145.974% |
| IDenta Corp. | 1.01 Million USD | -1958.938% |
| Interpace Biosciences, Inc. | 28.15 Million USD | 25.914% |
| Integrative Health Technologies, Inc. | 297.94 Thousand USD | -6901.345% |
| InVitro International | 78.99 Thousand USD | -26308.781% |
| Lumos Diagnostics Holdings Limited | 19.72 Million USD | -5.734% |
| Many Bright Ideas Technologies Inc. | 129.29 Thousand USD | -16033.627% |
| Medical Imaging Corp. | 9.51 Million USD | -119.188% |
| NovelStem International Corp. | 4.2 Million USD | -395.956% |
| Optigenex Inc. | 9.57 Million USD | -117.962% |
| PharmChem, Inc. | 558.64 Thousand USD | -3634.075% |
| Proteome Sciences plc | 18.48 Million USD | -12.825% |
| Response Genetics, Inc | 15.86 Million USD | -31.47% |
| Rennova Health, Inc. | 49.66 Million USD | 58.0% |
| RushNet, Inc. | 6.23 Million USD | -234.354% |
| ScreenPro Security Inc. | 1.6 Million USD | -1203.29% |
| Stella Diagnostics Inc. | 18 Million USD | -15.856% |
| StageZero Life Sciences Ltd. | 8.2 Million USD | -154.27% |
| Todos Medical Ltd. | 50.15 Million USD | 58.41% |